Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||PV1019 + Radiotherapy|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PV1019||CHK2 Inhibitor 5||PV1019, a derivative of NSC109555, is an ATP-competitive inhibitor of CHK2, which leads to reduced CHK2 kinase activity and decreased tumor cell growth, and enhances the anti-tumor effects of chemotherapeutic agents (PMID: 19741151).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||high grade glioma||not applicable||PV1019 + Radiotherapy||Preclinical - Cell culture||Actionable||In a preclinical study, glioma cells treated with PV1019 before and after radiotherapy resulted in greater cell death in culture than compared to radiation treatment alone (PMID: 19741151).||19741151|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|